Biotech entity
pharma is the sole category represented across all 1 tracked stories. Kura Oncology is most often covered alongside KOMZIFTI, which appears in 1 of these 1 story. Kura Oncology appears in 1 tracked Biotech story from March 6, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Kura Oncology is most often covered alongside KOMZIFTI, which appears in 1 of these 1 story. Kura Oncology appears in 1 tracked Biotech story from March 6, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kura Oncology. Shared-story counts are live from our verified record — not editorial picks.
Kura Oncology and Profound Medical reported fourth-quarter 2025 results, highlighting a pivotal shift toward commercial execution in precision oncology and medical technology. While both companies faced revenue headwinds, Kura's launch of KOMZIFTI and Profound's surprise earnings beat signal a maturing landscape for specialized therapies.
Kura Oncology is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
